Clinical Trials Directory

Trials / Completed

CompletedNCT06236165

Clinical Study Evaluating Efficacy, Safety and Molecular Mechanism of N-acetylcysteine Supplementation in Patients With Hepatic and Post Hepatic Jaundice

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
44 (actual)
Sponsor
Tanta University · Academic / Other
Sex
All
Age
18 Years – 70 Years
Healthy volunteers
Not accepted

Summary

Investigating the efficacy, safety, and molecular mechanism of N-acetylcysteine supplementation in improving elevated direct bilirubin level and liver function tests in patients with hepatic and post-hepatic jaundice.

Conditions

Interventions

TypeNameDescription
DRUGN-acetylcysteinePatients will receive oral N-acetylcysteine 600 mg twice daily in addition to supportive treatment, for 3 months.

Timeline

Start date
2024-02-14
Primary completion
2025-01-22
Completion
2025-01-22
First posted
2024-02-01
Last updated
2025-07-30

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT06236165. Inclusion in this directory is not an endorsement.

Clinical Study Evaluating Efficacy, Safety and Molecular Mechanism of N-acetylcysteine Supplementation in Patients With (NCT06236165) · Clinical Trials Directory